Morepen Laboratories Limited

NSEI:MOREPENLAB 株式レポート

時価総額:₹42.7b

Morepen Laboratories 過去の業績

過去 基準チェック /46

Morepen Laboratoriesは、平均年間11.3%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.4% 13.6%収益成長率で 成長しています。 Morepen Laboratoriesの自己資本利益率は11.9%であり、純利益率は7.4%です。

主要情報

11.3%

収益成長率

7.8%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率13.6%
株主資本利益率11.9%
ネット・マージン7.4%
前回の決算情報30 Sep 2024

最近の業績更新

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Recent updates

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Aug 20
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Jul 05
Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Jun 13
Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Apr 23
Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Nov 23
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Aug 10
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 21
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Apr 05
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Sep 14
Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

May 21
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Mar 12
Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Feb 22
Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 07
Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Jan 21
Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Jan 03
Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Dec 16
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Nov 28
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

収支内訳

Morepen Laboratories の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:MOREPENLAB 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Sep 2417,7481,3132,0170
30 Jun 2417,5711,1771,9980
31 Mar 2417,0199621,9350
31 Dec 2316,4227612,1270
30 Sep 2315,4335311,9580
30 Jun 2315,2384772,8840
31 Mar 2314,2203871,6540
31 Dec 2214,2704281,8000
30 Sep 2214,7655531,8430
30 Jun 2214,7217682,6040
31 Mar 2215,5581,0171,7240
31 Dec 2114,7431,1611,8090
30 Sep 2113,8541,1841,5890
30 Jun 2113,2951,0822,0920
31 Mar 2111,9809711,4070
31 Dec 2011,1368141,3450
30 Sep 2010,3806841,2790
30 Jun 209,1834531,6780
31 Mar 208,5843361,1430
31 Dec 198,7313311,1610
30 Sep 198,5303121,1180
30 Jun 198,1173401,4740
31 Mar 197,7142889950
31 Dec 187,2582529800
30 Sep 186,6722678790
30 Jun 186,4363088410
31 Mar 186,1012968070
31 Mar 175,9912367390
31 Mar 164,8611286160
31 Mar 154,014215170
31 Mar 143,670-288074

質の高い収益: MOREPENLAB 非現金収入 のレベルが高いです。

利益率の向上: MOREPENLABの現在の純利益率 (7.4%)は、昨年(3.4%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: MOREPENLABの収益は過去 5 年間で年間11.3%増加しました。

成長の加速: MOREPENLABの過去 1 年間の収益成長率 ( 147.1% ) は、5 年間の平均 ( 年間11.3%を上回っています。

収益対業界: MOREPENLABの過去 1 年間の収益成長率 ( 147.1% ) はPharmaceuticals業界20%を上回りました。


株主資本利益率

高いROE: MOREPENLABの 自己資本利益率 ( 11.9% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘